Baxter

Baxter International, Inc. engages in the provision of a portfolio of essential renal and hospital products, including acute and chronic dialysis, sterile IV solutions, infusion systems and devices, parenteral nutrition therapies, premixed and oncolytic injectable, bio surgery products and anesthetics, drug reconstitution systems and pharmacy automation, software, and services. It operates through the following segment: Americas, Europe, Middle East and Africa (EMEA), Asia-Pacific (APAC), and Hillrom. The Americas, EMEA, and APAC segments offer a portfolio of essential healthcare products. The Hillrom segment provides digital and connected care solutions and collaboration tools, including smart bed systems, patient monitoring and diagnostic technologies, respiratory health devices and advanced equipment for the surgical space. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Baxter reports robust Q4 sales, eyes growth amid operational challenges

Baxter International's Q4 2022 performance reflects strong sales growth and strategic actions to enhance agility and market responsiveness.
While facing challenges such as lower-than-expected earnings and supply chain constraints, the company is focused on cost reduction and operational improvements.
Opportunities lie in R&D investments, cost synergies from the Hillrom integration, and improving backlog and backorders, positioning Baxter for future growth.
Analysts' concerns about operating margins and financial outlook for 2023 highlight the need for continued efficiency measures and strategic planning.

Baxter beats Q1 expectations, plans spin-off for strategic clarity

Baxter's Q1 performance exceeded expectations with sales growth in key segments and adjusted EPS surpassing guidance.
The company is progressing well with its strategic initiatives, including the spin-off of Renal Care and new operating model.
Challenges in legacy businesses and soft hospital spending highlight areas for improvement, while opportunities lie in new product launches and margin enhancement strategies.
Overall, Baxter's focus on innovation, operational efficiency, and market trends positions it for long-term success and growth.

Baxter exceeds Q2 expectations, eyes growth amid strategic actions

Baxter's Q2 2023 performance showcased resilience and adaptability in a dynamic healthcare market, with strategic actions underway to drive operational efficiency and growth.
The company's focus on innovation, safety, and market responsiveness positions it well for future success, despite challenges such as pending divestitures and market uncertainties.
With a strong performance, growth opportunities in key segments, and operational improvements driving margin expansion, Baxter is navigating challenges to capitalize on future growth prospects.

Baxter beats Q3 expectations, eyes growth through strategic initiatives

Baxter's Q3 2023 performance exceeded expectations, with a focus on strategic priorities and the upcoming Kidney Care segment separation.
The company's strengths lie in maintaining market share, operational efficiencies, and maximizing shareholder value through financial analysis.
Challenges include renegotiating contracts, rising energy costs, and achieving organic growth amidst market dynamics.
Opportunities for Baxter include growth through cost improvements, margin programs, and product launches in 2024.

Baxter surpasses Q4 expectations, eyes growth amid inflation challenges

Baxter's Q4 2023 performance exceeded expectations, driven by growth in key segments and strategic initiatives, setting the stage for continued success in 2024.
Despite challenges like inflation and flat growth in certain segments, Baxter's focus on margin improvement, debt management, and growth strategies positions the company for future resilience.
With a strong outlook for 2024, Baxter aims to capitalize on opportunities for growth, margin improvement, and market expansion, supported by a solid financial foundation and strategic priorities.

Baxter surpasses Q1 expectations with focus on innovation and growth

Baxter's Q1 2024 performance exceeded expectations, driven by strong sales growth and focus on innovation, despite challenges in certain segments and geographies.
The company's strategic strengths lie in diverse growth drivers, strong segment margins, and geographic expansion successes, positioning it for continued success.
Addressing challenges in underperforming segments and markets, along with seizing opportunities for improvement and expansion, will be crucial for Baxter's future growth.
With a clear focus on innovation, margin expansion, and shareholder value maximization, Baxter aims to navigate challenges and capitalize on growth prospects for sustained success.

Baxter exceeds Q2 expectations, plans Kidney Care separation for growth

Baxter International's Q2 2024 earnings call highlighted robust performance, strategic initiatives, and a positive outlook for sales growth and earnings per share.
The company's focus on margin improvement, innovation, and operational efficiency positions it well for sustained growth and shareholder value creation.
While facing challenges in certain segments and external factors, Baxter's proactive approach and strong fundamentals offer opportunities for future expansion and success.
Investors can look forward to Baxter's continued commitment to driving growth, expanding margins, and delivering innovative healthcare solutions.

Baxter reports solid Q3 performance amidst challenges and growth opportunities

Baxter International demonstrated resilience in Q3 2024 with sales growth and earnings exceeding expectations despite challenges.
The company's focus on operational efficiency, cost containment, and strategic divestitures positions it well for future growth.
Challenges from Hurricane Helene impact and Kidney Care separation are being addressed with a clear vision for sustained performance.
Opportunities for growth and margin expansion underscore Baxter's commitment to delivering value to shareholders and patients.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Baxter International, Inc. engages in the provision of a portfolio of essential healthcare products including acute and chronic dialysis therapies, sterile intravenous (IV) solutions, infusion systems and devices, parenteral nutrition therapies, inhaled anesthetics, generic injectable pharmaceuticals, surgical hemostat and sealant products, surgical equipment, smart bed systems, patient monitoring and diagnostic technologies, and respiratory health devices. It operates through the following segments: Americas, Europe, Middle East and Africa (EMEA), Asia-Pacific (APAC), and Hillrom. The Americas, EMEA, and APAC segments offer a portfolio of essential healthcare products. The Hillrom segment provides digital and connected care solutions and collaboration tools, including smart bed systems, patient monitoring and diagnostic technologies, respiratory health devices, and equipment for the surgical space. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.

The headline numbers for Baxter (BAX) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Baxter (BAX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

Baxter (BAX) reports better-than-expected third-quarter earnings and sales. The company completes the divestment of its BioPharma Solution business.

Baxter (BAX) Beats on Q3 Earnings, Divests BioPharma Business

Baxter International Inc. (NYSE:BAX ) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Joe Almeida - Chairman, Chief Executive Officer Joel Grade - Executive Vice President, Chief Financial Officer Brian Stevens - Senior Vice President, Chief Accounting Officer, Controller, former Interim CFO Clare Trachtman - Senior Vice President, Chief Investor Relations Officer Conference Call Participants Matt Miksic - Barclays Vijay Kumar - Evercore ISI Rick Wise - Stifel Pito Chickering - Deutsche Bank Robbie Marcus - J.P. Morgan Travis Steed - Bank of America Securities Joanne Wuensch - Citi Danielle Antalffy - UBS Operator Good morning, ladies and gentlemen, and welcome to Baxter International's Third Quarter 2023 Earnings Conference Call.

Baxter International Inc. (BAX) Q3 2023 Earnings Call Transcript

Baxter International on Thursday beat Wall Street expectations for third-quarter revenue and profit, as a recovery in surgical procedure volumes after the pandemic helped drive the demand for its medical devices higher.

Baxter International beats Q3 profit estimates on strong demand for medical devices

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the third quarter of 2023. “Baxter continues to successfully execute upon the slate of strategic actions we announced at the outset of 2023,” said José (Joe) E. Almeida, chairman, president and chief executive officer. “These initiatives are centered on enhancing business performance and increasing innovation, to drive incremental value for all of our stakeholders. This pr.

Baxter Reports Third-Quarter 2023 Results

Haemonetics

Insulet

These top-rated Zacks Medical sector stocks are very attractive ahead of their quarterly reports on Thursday, November 2 with now looking like an ideal time to invest.

3 Medical Products Stocks to Consider as Earnings Approach

Stryker

Investors looking for stocks in the Medical - Products sector might want to consider either Baxter International (BAX) or Stryker (SYK). But which of these two stocks is more attractive to value investors?

BAX vs. SYK: Which Stock Is the Better Value Option?

Baxter's (BAX) third-quarter results are likely to reflect growth in elective surgical procedures, offset by currency movement. Hillrom's products might have boosted sales.

Baxter (BAX) to Report Q3 Earnings: Is a Beat in Store?

Abbott Labs

Intuitive Surgical

Johnson & Johnson

Medtronic

Results from Johnson & Johnson NYSE: JNJ and Abbott Laboratories NYSE: ABT foreshadow good news for MedTech investors. Both companies outperformed on the top and bottom lines, driven by broad strength in their MedTech units.

The Value Deepens for Medtech Stocks: Reversal Imminent

Baxter's (BAX) latest offering is likely to enable a more digitally-connected primary care examination and support faster diagnosis for earlier treatment of eye conditions.

Baxter's (BAX) New Launch to Enable Earlier Treatment of Eye

DexCom

Penumbra

ResMed

Zimmer Biomet Hlds

Some investors have worried that new weight-loss drugs could undermine demand for some medical devices.

6 Medical Device Stocks Primed to Bounce Back

DaVita

Novo Nordisk ended its kidney outcome trial early after interim results showed the efficacy of its drug-Ozempic in delaying the progression of chronic kidney disease. Stocks of medical equipment major, Baxter International, and kidney care servicing specialist, DaVita, have faced significant declines since the news. We posit why the market may be overreacting to the news.

Should You Buy Baxter Or DaVita After The Fallout From The Ozempic Trial?

NEW YORK--(BUSINESS WIRE)-- #A--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Baxter International, Inc. (NYSE: BAX) on behalf of long-term stockholders following a class action complaint that was filed against Baxter on July 12, 2023 with a Class Period from May 25, 2022 to February 8, 2023. Our investigation concerns whether the board of directors of Baxter have breached their fiduciary duties to the company. On Febr.

BAXTER ALERT: Bragar Eagel & Squire, P.C. is Investigating Baxter International, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

A drug made by a rival tested well in a clinical trial for kidney disease. That treatment is currently a very hot product, but for different indications.

Why Investors Punished Baxter International Stock Today

Novo Nordisk

Fresenius Medical Care

Eli Lilly

Over $5bn in value was wiped from the three main operators in the dialysis market after a clinical trial update that offers hope for thousands of diabetes sufferers with kidney disease. Earlier, Novo Nordisk (NYSE:NVO) revealed that its Ozempic – a weekly jab which also doubles as a weight-loss aid – had proven successful in treating the new patient group mentioned above.

Novo Nordisk data knocks $5bn from the value of three leading dialysis companies

Boston Scientific

The trial success of Novo Nordisk's hit drug against kidney failure sent shares of a German kidney dialysis services firm plummeting on Wednesday.

Dialysis company shares plunge after Ozempic trial success vs. kidney trouble

Boston Properties

Fidelity National Information

SPDR Portfolio Long Term Treasury ETF

AT&T

V.F.

Walgreens

Warner Bros Discovery Inc

If you own long-term Treasurys, you'd be hard-pressed to find a worse investment the S&P 500. But it's possible.

Only 7 Stocks Burn Investors Worse Than Long-Term Treasurys

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced it has appointed Joel Grade as executive vice president and chief financial officer (CFO), reporting to Baxter chairman, president and CEO, José (Joe) E. Almeida, effective Oct. 18, 2023. At that time, Brian Stevens, who has served as the company's interim CFO since May 31, 2023, will transition to his prior role as senior vice president, chief accounting officer and controller. “Joe.

Baxter Appoints Joel Grade Chief Financial Officer

BOSTON & NEW YORK--(BUSINESS WIRE)--Advent International (“Advent”), one of the largest and most experienced global private equity investors, and Warburg Pincus, a leading global growth investor, today announced the completion of their previously announced acquisition of Baxter International Inc.'s (NYSE:BAX) BioPharma Solutions (BPS) business. The business will now be a standalone contract development and manufacturing organization (CDMO) operating under the name Simtra BioPharma Solutions (“S.

Advent International and Warburg Pincus Complete Acquisition of Baxter's BioPharma Solutions Business

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its third-quarter 2023 financial results on Thursday, November 2, 2023 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://conferencingportals.com/event/etCeELhb to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.baxter.c.

Baxter to Host Third-Quarter 2023 Financial Results Conference Call for Investors

NEW YORK, NY / ACCESSWIRE / September 11, 2023 / If you suffered a loss on your Baxter International Inc. (NYSE:BAX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/baxter-lawsuit-submission-form?prid=47638&wire=1 or contact Joseph E. Levi, Esq.

SHAREHOLDER ALERT: Potential Recovery for Baxter International Inc. (BAX) Investors Affected by Stock Drop - Levi & Korsinsky Pursuing Class Action Lawsuit

NEW YORK, NY / ACCESSWIRE / September 11, 2023 / If you suffered a loss on your Baxter International Inc. (NYSE:BAX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/baxter-lawsuit-submission-form?prid=47605&wire=1 or contact Joseph E. Levi, Esq.

SHAREHOLDER ALERT: Potential Recovery for Baxter International Inc. (BAX) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit

NEW YORK , Sept. 11, 2023 /PRNewswire/ -- Attention Baxter International Inc. ("Baxter") (NYSE: BAX) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between May 25, 2022 and February 8, 2023.

SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Baxter Investors of a Lead Plaintiff Deadline of September 11, 2023

LOS ANGELES, CA / ACCESSWIRE / September 11, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Baxter International Inc. ("Baxter" or "the Company") (NYSE:BAX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 25, 2022 and February 8, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before September 11, 2023.

FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in Baxter International Inc. with Losses to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming September 11, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Baxter International Inc. (“Baxter” or the “Company”) (NYSE: BAX) securities between May 25, 2022 and February 8, 2023, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. On February 9, 2023, before the market opened, Baxter r.

News for Baxter Stock (BAX)